PHASE I TRIAL OF INTRAVENOUS FENRETINIDE (4-HPR) FOR PATIENTS WITH HEMATOLOGI

针对血液病患者静脉注射芬维A胺 (4-HPR) 的 I 期试验

• 批准号: 7716693
• 负责人: ANN F MOHRBACHER
• 金额: $ 15.5万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-20 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716693
• 关键词: Adult; Biological Availability; Breast; Cell Line; Child; Computer Retrieval of Information on Scientific Projects Database; Drug Formulations; Fenretinide; Funding; Grant; Hematologic Neoplasms; Institution; Intravenous; Intravenous Fat Emulsions; Malignant neoplasm of ovary; Neuroblastoma; Oral; Patients; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Research; Research Personnel; Resources; Safety; Serum; Source; Testing; Titrations; Toxic effect; United States National Institutes of Health; cytotoxicity; design; leukemia; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase I Trial of Intravenous Fenretinide (4-HPR) for patients with Hematologic Malignancies using an accelerated titration design. Fenretinide has been tested in oral formulation in treatment of breast and ovarian cancer in adults, and in neuroblastoma in children. Poor bioavailability of the oral drug precludes reaching serum levels shown to have direct tumor cytotoxicity for leukemia and lympoma cell lines. This phase I trial will assess safety, feasibilty, and toxicity of a new intravenous lipid emulsion formulation of fenretinide in patients with Hematologic Malignancies.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这是使用加速滴定设计的血液系统恶性肿瘤患者的静脉注射芬替胺（4-HPR）的I期试验。 芬雷丁苷在成人的乳腺癌和卵巢癌治疗以及儿童神经母细胞瘤中的口服配方中进行了测试。 口服药物的生物利用度较差，无法达到血清水平的血清水平直接肿瘤细胞毒性，可用于白血病和淋巴瘤细胞系。 该阶段I试验将评估血液系统恶性肿瘤患者芬雷丁汀的新静脉脂质乳液配方的安全性，可行性和毒性。